Allergan (AGN) Tops Q1 EPS by 24c, Offers Q2 and Updated FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- CoreWeave stock drops on insider selling notice
- Sysco calls on Teamsters to end LA strike after economic deal reached
Stifel Reiterates Hold Rating on Allergen (AGN), Remains Sidelined Awaiting Signs of a Strategic Shift
May 7, 2019 4:47 PM EDTStifel analyst Annabel Samimy reiterated a Hold rating and $175.00 price target on Allergen (NYSE: AGN).
The analyst comments "While AGN recognizes the need for change, there was no specific directive offered, yet. In the meantime, AGN remains focused on its core business,... More



